A new drug or treatment typically fails not because it is unsafe, but because the trials designed to test it are poorly planned. The Edinburgh Trials Methodology Hub aims to fix that by studying why some clinical trials succeed while others fail, and then building better methods for designing and analysing future studies. This matters because the current path from lab to clinic is inefficient. Many promising interventions never reach patients, not because they lack biological effect, but because the trials themselves are flawed—wrong patient groups, wrong doses, or poor statistical design. The Hub will bring together scientists who understand disease mechanisms with experts in trial methodology, and will also give ongoing trials access to genetic and imaging tools that can identify which patient subgroups are most likely to benefit. If this research succeeds, it will not produce a new drug directly. Instead, it will improve the infrastructure that quietly determines which treatments ever get tested properly. Future clinical trials could become smaller, faster, and more likely to show real effects—meaning fewer false starts and more effective therapies reaching the clinic. This is fundamental methodology research, but its impact on how medicines are developed could be substantial.
View original technical description
When a new drug is being developed it passes through several stages of development. After the initial preclinical development, first in man studies evaluate the safety and potential side effects. Then explanatory studies optimise the treatment, for example in terms of which patients have the greatest potential to benefit and what dose to use. Such studies look at underlying disease mechanisms, and test whether an intervention has the potential to be useful in practice. Then pragmatic studies test whether any potential benefit seen in the explanatory trials can be realised in clinical practice. For non-drug treatments the terminology is different, but the development path is similar. There are many reasons why an intervention can fail as it progresses through the stages of development, and the aim of the Edinburgh Trials Methodology Hub is to undertake a programme of research which will help to increase the chances of success at each step of the development process. We shall attempt to learn lessons both from successful development programmes and also from others which have failed. This will be achieved by encouraging interdisciplinary cllaboration between the scientists who are working on understanding underlying disease mechanisms and those with experience in clinical trials methodology. The end results will be to improve the design and analysis of future clinical trials, and to provide researchers with trials support and access to genetic and imaging technologies to identify patient subgroups with the greatest potential to benefit within ongoing trials.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know